Trevi Therapeutics Takes Major Steps in Clinical Trials
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering biopharmaceutical company, is making remarkable strides in the clinical development of Haduvio™, a novel treatment aimed at chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Recent updates from Trevi highlight that its Phase 2b CORAL trial has achieved 50% enrollment, a pivotal advancement as the company moves towards a sample size re-estimation anticipated for December 2024.
The CORAL trial is crucial as it explores the effectiveness of Haduvio™, which is an extended-release oral formulation of nalbuphine. This innovative approach is designed to engage both central and peripheral pathways involved in the cough reflex, potentially offering relief to those suffering from chronic cough conditions. The upcoming sample size re-estimation will help determine if the current enrollment of 160 participants will remain, increase, or be reconsidered due to possible futility. If no modifications are required, top-line results are expected in the first half of 2025.
Progress in Safety Assessments
In addition to the CORAL trial, Trevi has concluded dosing in its Human Abuse Potential (HAP) study, which is essential for evaluating the abuse risk associated with drugs that affect the central nervous system. Top-line results from this study are also projected for release in December 2024, and their outcome will significantly influence Trevi's regulatory submissions.
RIVER Trial Insights
The RIVER trial, focused on RCC, has successfully met its planned sample size. However, enrollment remains open to fine-tune stratification targets. Trevi anticipates releasing top-line results for this trial in the first quarter of 2025, marking another critical endpoint for the company.
Addressing Unmet Medical Needs
Trevi Therapeutics is dedicated to addressing the substantial unmet medical needs in chronic cough, a condition that affects patient quality of life and may lead to severe complications or increased mortality in IPF. The absence of approved treatments for chronic cough in IPF or RCC in the United States underscores the potential impact Haduvio™ could have if it proves effective.
Recent Developments and Financial Health
Recently, Trevi Therapeutics has garnered attention for its advancements with Haduvio. The company has received positive coverage from Raymond James, which initiated coverage with an Outperform rating, citing the potential of Haduvio in treating chronic cough. During its Second Quarter 2024 Earnings Conference Call, Trevi reported a net loss of $12.4 million, which highlights the typical challenges faced by clinical-stage biopharmaceutical companies. Despite these losses, Trevi has secured funding that extends until 2026, allowing it to continue advancing its clinical programs.
Market Performance and Investor Insights
The recruitment for the RIVER trial for RCC is at 80%, with crucial data expected by the end of 2024. The CORAL Phase 2b trial continues to enroll participants, with topline data projected in the first half of 2025. Analyst firms such as H.C. Wainwright and EF Hutton have echoed similar sentiments, initiating coverage with a Buy rating based on encouraging clinical data suggesting a reduced risk in ongoing trials.
Overall, the continuing progress in Trevi Therapeutics' trials for Haduvio reflects a significant market opportunity. In an industry often hampered by unmet medical needs, Trevi's advancements present a hopeful narrative for both the company and its investors.
Frequently Asked Questions
What is Trevi Therapeutics focusing on with Haduvio™?
Trevi Therapeutics is focusing on developing Haduvio™, an investigational therapy for chronic cough related to IPF and RCC.
What are the key milestones Trevi Therapeutics has achieved?
The company has achieved 50% enrollment in the CORAL trial and completed dosing in its Human Abuse Potential study.
When are the results for the ongoing trials expected?
Top-line results for the CORAL trial are expected in the first half of 2025, and for the HAP study in December 2024.
What is the current financial state of Trevi Therapeutics?
Trevi reported a net loss of $12.4 million but has funding secured until 2026.
How is Trevi Therapeutics perceived in the market?
Analyst firms have published positive ratings, indicating optimism about Trevi's potential and performance in clinical trials.
